SCHEDULE 13G: Sio Capital Management Discloses 7.19% Stake in PMV Pharmaceuticals
Beneficial Ownership Report
Sio Capital Management, LLC has reported a 7.19% beneficial ownership stake in PMV Pharmaceuticals, Inc. as of March 31, 2025, according to a recent Schedule 13G filing.
Summary
- Sio Capital Management, LLC, a Delaware limited liability company and registered investment adviser, has filed a Schedule 13G with the SEC.
- The filing indicates that Sio Capital Management, LLC beneficially owns 3,735,396 shares of common stock in PMV Pharmaceuticals, Inc.
- This ownership represents 7.19% of PMV Pharmaceuticals, Inc.'s outstanding common stock.
- The percentage is calculated based on 51,933,604 shares of common stock outstanding as of March 3, 2025, as reported in the Issuer's Form 10-K.
- Sio Capital Management, LLC holds both shared voting power and shared dispositive power over these 3,735,396 shares.
- The beneficial ownership is held by certain affiliated funds for which Sio Capital Management, LLC acts as an investment adviser.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment, which can be viewed positively as a vote of confidence in the issuer. However, the document itself is a routine regulatory disclosure and does not contain performance-related news.
Positives
- A significant stake (7.19%) by an institutional investor like Sio Capital Management, LLC can be interpreted as a vote of confidence in PMV Pharmaceuticals, Inc.'s future prospects.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure indicating a significant ownership stake by an institutional investor in a publicly traded pharmaceutical company. Such filings are routine when an investor crosses the 5% beneficial ownership threshold, reflecting an investment decision rather than operational or strategic updates from the company itself.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may positively influence investor sentiment and potentially the stock price, as it signals confidence from a professional investment firm.
Key Dates
| Date | Description |
|---|---|
| 2025-03-03 | Date of Issuer's Form 10-K filing, reporting 51,933,604 shares of common stock outstanding. |
| 2025-03-31 | Date of event requiring the filing of this statement, reflecting Sio Capital Management's beneficial ownership. |
| 2025-04-04 | Date of filing of the Schedule 13G statement by Sio Capital Management, LLC. |
Keywords
PMV Pharmaceuticals, Sio Capital Management, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.